Ivosidenib was approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed or refractory IDH1-mutated AML in 2018 (38), and also as a front-line therapy for newly diagnosed elderly patients 75 years or older or who are ineligible to receive intensive chemotherapy in 2019, based on promising results of phase I-II clinical trials (39). The gene discussed is IDH1; the disease is acute myeloid leukemia.